An osteoid variant of cutaneous melanoma in a dog detected by S100 and melan a markers.

Osteoid malignant melanoma is a rare type of melanoma described in humans and dogs with some areas of bone differentiation. In this tumour, the origin of the bone matrix remains unclear. We report one case of this variant with, for the first time, a cutaneous origin in a dog. Malignant melanomas are aggressive tumours. Amelanotic tumours are sometimes difficult to recognize as they require immunohistochemical evaluation for an adequate diagnosis and we have used anti-vimentin, S100, and melan A antibodies for identification. Melan A is less sensitive but more specific than S100 in identifying amelanotic melanomas. This tumour was positive for vimentin, S100 and melan A, including the areas of osteoid. These results suggest osteoid differentiation of tumour cells rather than induced stromal metaplasia.

Emericella nidulans as an agent of guttural pouch mycosis in a horse.

A case is reported in a 9-year-old Anglo-Arab horse with guttural pouch mycosis caused by Emericella nidulans. Acute death occurred by exsanguination following erosion of the external carotid artery. Histopathological examination of the mycotic plaque demonstrated septate hyphae, conidial heads, hülle cells and mature cleistothecia containing characteristic ascospores. Specific identification was confirmed by culture. In accordance with previous reports, Emericella nidulans should be considered as the major agent of guttural pouch mycosis in Equidae.

Subcutaneous Taenia crassiceps cysticercosis in a dog.

Taenia crassiceps larvae, typically found in rodents, were recovered from fluctuant subcutaneous cystic lesions in a dog. Differential diagnosis included Taenia crassiceps cysticercosis, other metacestode infections, and pseudotumoral skin diseases.

Reversible effects of long-term treatment with D-Trp6-LH-RH-microcapsules on pituitary-gonadal axis, spermatogenesis and prostate morphology in adolescent and adult dogs.

The effect of long term treatment with D-Trp6-LH-RH in microcapsules (GnRH-A) on pituitary gonadal axis was studied in a adolescent and adult Fox-terrier dogs. They received intramuscularly 50 micrograms/GnRH-A/kg, on day 1 and 21 and every 4 weeks thereafter. Three adult dogs received 4 injections. cLH, cFSH and T levels were undetectable on day 7. Detectable then normal levels occurred 60 and 90 days respectively after the last injection on day 77. Testis thickness was respectively 22.1 +/- 0.8 mm and 16.3 +/- 0.8 mm on days 0 and 77; initial values were observed 90 days later. Spermatozoa disappeared from the ejaculate on day 21 in 2 dogs; reappearance and complete recovery were observed on days 161-175 and 252 respectively. Histological findings showed on day 91 atrophic lesions of testis and prostate and spermatogonia were present in all seminiferous tubules. After recovery a normal histological appearance was noticed. Three adolescent 29 weeks old dogs received 14 injections, the last one on day 357. cLH, cFSH and T levels were undetectable only from day 105. Testis thickness were respectively 15.8 +/- 0.7 mm, 18.1 +/- 0.7 mm, 12.5 +/- 0.3 mm and 21.4 +/- 0.7 mm on day 0, 21, 357 and 490. Initially, no spermatozoa were present in the ejaculates, they appeared in 2 dogs after 2 months for 20 to 40 days then disappeared until day 449. Normal semen characteristics were observed in all three dogs on day 581. Histological findings on day 371 were comparable to those observed in the adult dogs. This study demonstrates that longterm treatment with D-Trp6-LH-RH in microcapsules leads to a reversible inhibition of spermatogenesis in dogs. The delayed response in adolescent dogs might be due to a transient resistance to therapy related to.

Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy.

In two parallel studies, bitches with mammary tumour received single intralesional injections of BCG (1 mg: 10(7) living bacteria) and Corybacterium parvum (10(9) killed bacteria) (53 bitches) or C. parvum alone (129 bitches) at the same dosage. Control groups received injections, following the same protocol, of 1 ml BCG suspension medium diluted in saline in the first study (51 bitches) or no injections at all (120 bitches in the second study). A block dissection, including mammary tumours, adjacent mammary glands, and regional lymph nodes, was performed 2 weeks later in all animals. On the basis of histologically confirmed malignant tumours, 48 bitches (25 treated by-immunotherapy and 23 controls) in the first study and 67 bitches (30 treated by immunotherapy and 37 controls) in the second study remained for postsurgical follow-up. The clinical tolerance of the treatment was generally good. No significant differences were found in cumulative survival rates between treated and control group in either studies.

[Evaluation of hepatic pathology of bovines by a blood sample. Relations with histopathologic findings]. / Evaluation de la pathologie hépatique des bovins sur un prélèvement de sang. Relations avec l'histopathologie.

Three groups of twelve cows were chosen after slaughter on the basis of their state of liver damage. First group of cows was normal (no visible hepatic lesion : N group); second group (CD group) had cholangitis lesions related to Fasciola hepatica; and the last group (AN) had severe liver damages. Histopathologic examinations, various metabolic determinations in plasma and an immunologic detection of Fasciola hepatica were performed on hepatic tissue or blood samples. Results showed that gamma-GT, GLDH, albumin, globulins and total protein levels in plasma were significatively different between N group and CD or AN groups. Comparison between CD group and AN group showed that GLDH activities were significatively higher and albumin concentrations significatively lower in AN group than in CD group. Immunological test showed that Fasciola hepatica was the main cause of the liver lesions. It was concluded that an hepatic blood profile should include gamma-GT, GLDH and albumin determinations and a Fasciola hepatica serological test. Other hepatic tests are presented to complete the hepatic profile.